Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Nagase T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Oze T, et al. Among authors: mochizuki k. J Gastroenterol. 2011 Jul;46(7):944-52. doi: 10.1007/s00535-011-0403-0. Epub 2011 May 7. J Gastroenterol. 2011. PMID: 21552988 Clinical Trial.
Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.
Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. Kurokawa M, et al. Among authors: mochizuki k. Hepatol Res. 2009 May;39(5):432-8. doi: 10.1111/j.1872-034X.2008.00477.x. Epub 2009 Jan 16. Hepatol Res. 2009. PMID: 19207583
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.
Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N. Kurashige N, et al. Among authors: mochizuki k. J Gastroenterol. 2009;44(8):864-70. doi: 10.1007/s00535-009-0076-0. Epub 2009 May 28. J Gastroenterol. 2009. PMID: 19475333 Clinical Trial.
Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Kaytayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Oze T, et al. Among authors: mochizuki k. J Hepatol. 2011 Apr;54(4):604-11. doi: 10.1016/j.jhep.2010.07.043. Epub 2010 Dec 9. J Hepatol. 2011. PMID: 21145907 Clinical Trial.
Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, Mita E, Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Inoue Y, et al. Among authors: mochizuki k. J Med Virol. 2011 Mar;83(3):419-27. doi: 10.1002/jmv.21975. J Med Virol. 2011. PMID: 21264862
Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Hosui A, Miyagi T, Ishida H, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Oze T, et al. Among authors: mochizuki k. J Gastroenterol. 2011 Aug;46(8):1031-7. doi: 10.1007/s00535-011-0409-7. Epub 2011 May 3. J Gastroenterol. 2011. PMID: 21538029
Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N. Hiramatsu N, et al. Among authors: mochizuki k. J Gastroenterol. 2011 Nov;46(11):1335-43. doi: 10.1007/s00535-011-0455-1. Epub 2011 Aug 20. J Gastroenterol. 2011. PMID: 21858637
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Kurokawa M, et al. Among authors: mochizuki k. J Gastroenterol. 2012 May;47(5):577-85. doi: 10.1007/s00535-011-0522-7. Epub 2012 Jan 11. J Gastroenterol. 2012. PMID: 22231575 Clinical Trial.
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Oze T, et al. Among authors: mochizuki k. J Viral Hepat. 2009 Aug;16(8):578-85. doi: 10.1111/j.1365-2893.2009.01116.x. Epub 2009 Jun 22. J Viral Hepat. 2009. PMID: 19552663
1,332 results